Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Dal Pan

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|June 20, 2020
Postmarketing Safety-Related Regulatory Actions for New Therapeutic Biologics Approved in the United States 2002-2014: Similarities and Differences With New Molecular EntitiesIlynn Bulatao, Ellen Pinnow, Brendan Day, et al.
Pain Medicine (Malden, Mass.)|August 4, 2021
Patient-Reported Opioid Analgesic Use After Discharge from Surgical Procedures: A Systematic ReviewCeleste A Mallama, Christina Greene, Apostolos A Alexandridis, et al.
Pain Medicine (Malden, Mass.)|March 26, 2025
Patient-Reported Duration of Opioid Analgesic Use After Discharge from Surgical Procedures or Other Types of Acute Pain: A Scoping ReviewCandice L Collins, Karen England, Saranrat Conrad, et al.
Clinical Trials (London, England)|March 20, 2013
Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessmentTarek A Hammad, George A Neyarapally, Simone P Pinheiro, et al.
The American Journal of Drug and Alcohol Abuse|February 5, 2026
United States healthcare encounters for poisoning involving cannabis relative to other substancesSaranrat W Conrad, Christina R Greene, Gerald Dal Pan, et al.
Drug and Alcohol Dependence|June 5, 2026
U.S. Poison Center exposure cases involving marijuana and selected comparator substancesSara Karami, Rose G Radin, Christina R Greene, et al.
Clinical Pharmacology and Therapeutics|December 22, 2017
Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014Ellen Pinnow, Sania Amr, Søren M Bentzen, et al.
Clinical Pharmacology and Therapeutics|April 6, 2023
Assessment of the Impact of Mandated Postmarketing Pediatric-Focused Safety Reviews on Safety-Related Regulatory Actions 2013-2019Mohamed Mohamoud, Carmen Cheng, Debra Ryan, et al.
Addiction (Abingdon, England)|December 8, 2025
Variations in US county-level trends in buprenorphine use, 2018-2022Taylor W Lefler, Grace Chai, Sonal Goyal, et al.
Pharmacoepidemiology and Drug Safety|October 19, 2023
When can real-world data generate real-world evidence?Motiur Rahman, Gerald Dal Pan, Peter Stein, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|June 20, 2020
Postmarketing Safety-Related Regulatory Actions for New Therapeutic Biologics Approved in the United States 2002-2014: Similarities and Differences With New Molecular EntitiesIlynn Bulatao, Ellen Pinnow, Brendan Day, et al.
Pain Medicine (Malden, Mass.)|August 4, 2021
Patient-Reported Opioid Analgesic Use After Discharge from Surgical Procedures: A Systematic ReviewCeleste A Mallama, Christina Greene, Apostolos A Alexandridis, et al.
Pain Medicine (Malden, Mass.)|March 26, 2025
Patient-Reported Duration of Opioid Analgesic Use After Discharge from Surgical Procedures or Other Types of Acute Pain: A Scoping ReviewCandice L Collins, Karen England, Saranrat Conrad, et al.
Clinical Trials (London, England)|March 20, 2013
Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessmentTarek A Hammad, George A Neyarapally, Simone P Pinheiro, et al.
The American Journal of Drug and Alcohol Abuse|February 5, 2026
United States healthcare encounters for poisoning involving cannabis relative to other substancesSaranrat W Conrad, Christina R Greene, Gerald Dal Pan, et al.
Drug and Alcohol Dependence|June 5, 2026
U.S. Poison Center exposure cases involving marijuana and selected comparator substancesSara Karami, Rose G Radin, Christina R Greene, et al.
Clinical Pharmacology and Therapeutics|December 22, 2017
Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014Ellen Pinnow, Sania Amr, Søren M Bentzen, et al.
Clinical Pharmacology and Therapeutics|April 6, 2023
Assessment of the Impact of Mandated Postmarketing Pediatric-Focused Safety Reviews on Safety-Related Regulatory Actions 2013-2019Mohamed Mohamoud, Carmen Cheng, Debra Ryan, et al.
Addiction (Abingdon, England)|December 8, 2025
Variations in US county-level trends in buprenorphine use, 2018-2022Taylor W Lefler, Grace Chai, Sonal Goyal, et al.
Pharmacoepidemiology and Drug Safety|October 19, 2023
When can real-world data generate real-world evidence?Motiur Rahman, Gerald Dal Pan, Peter Stein, et al.
Pageof 4